NASDAQ:VRCA - Verrica Pharmaceuticals Stock Price, Forecast & News

Verrica Pharmaceuticals' stock was trading at $10.52 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, VRCA shares have decreased by 8.0% and is now trading at $9.68. View which stocks have been mosted impacted by Coronavirus.

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Verrica Pharmaceuticals in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Verrica Pharmaceuticals.

Verrica Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Tuesday, May 5th 2020. View our earnings forecast for Verrica Pharmaceuticals.

Verrica Pharmaceuticals Inc (NASDAQ:VRCA) issued its earnings results on Friday, March, 13th. The company reported ($0.31) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.30) by $0.01. View Verrica Pharmaceuticals' earnings history.

2 brokers have issued 12 month price objectives for Verrica Pharmaceuticals' shares. Their forecasts range from $20.00 to $24.00. On average, they expect Verrica Pharmaceuticals' share price to reach $22.00 in the next twelve months. This suggests a possible upside of 127.3% from the stock's current price. View analysts' price targets for Verrica Pharmaceuticals.

Media stories about VRCA stock have trended very negative on Friday, according to InfoTrie. InfoTrie ranks the sentiment of news coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Verrica Pharmaceuticals earned a news sentiment score of -3.3 on InfoTrie's scale. They also assigned news articles about the company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the company's share price in the next few days. View the latest news aboutVerrica Pharmaceuticals.

Verrica Pharmaceuticals saw a increase in short interest in the month of February. As of February 28th, there was short interest totaling 730,800 shares, an increase of 23.0% from the February 13th total of 594,100 shares. Based on an average trading volume of 66,300 shares, the days-to-cover ratio is presently 11.0 days. Approximately 5.7% of the company's stock are short sold. View Verrica Pharmaceuticals' Current Options Chain.

Some companies that are related to Verrica Pharmaceuticals include NextCure (NXTC), Madrigal Pharmaceuticals (MDGL), Supernus Pharmaceuticals (SUPN), Amneal Pharmaceuticals (AMRX), Opko Health (OPK), Akebia Therapeutics (AKBA), Aimmune Therapeutics (AIMT), Odonate Therapeutics (ODT), Kiniksa Pharmaceuticals (KNSA), Esperion Therapeutics (ESPR), Intra-Cellular Therapies (ITCI), CannTrust (CNTTF), Phoenix Tree (IMAB), Phathom Pharmaceuticals (PHAT) and Rocket Pharmaceuticals (RCKT).

Based on aggregate information from My MarketBeat watchlists, some companies that other Verrica Pharmaceuticals investors own include Gilead Sciences (GILD), AbbVie (ABBV), Aurora Cannabis (ACB), Exxon Mobil (XOM), CytomX Therapeutics (CTMX), Foamix Pharmaceuticals (FOMX), Global Blood Therapeutics (GBT), Progenics Pharmaceuticals (PGNX), Citigroup (C) and Enterprise Products Partners (EPD).

(VRCA) raised $75 million in an initial public offering on Friday, June 15th 2018. The company issued 5,000,000 shares at $14.00-$16.00 per share. BofA Merrill Lynch, Jefferies and Cowen acted as the underwriters for the IPO.

Verrica Pharmaceuticals trades on the NASDAQ under the ticker symbol "VRCA."

Shares of VRCA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of VRCA stock can currently be purchased for approximately $9.68.

Verrica Pharmaceuticals has a market capitalization of $249.61 million. The company earns $-28,210,000.00 in net income (profit) each year or ($1.13) on an earnings per share basis. Verrica Pharmaceuticals employs 16 workers across the globe. View additional information about Verrica Pharmaceuticals.

The official website for Verrica Pharmaceuticals is http://www.verrica.com/.

Verrica Pharmaceuticals' mailing address is 10 NORTH HIGH STREET SUITE 200, WEST CHESTER PA, 19380. The company can be reached via phone at 484-453-3300 or via email at [email protected]